Bellevue Group’s Vir Biotechnology VIR Stock Holding History

Bellevue Group’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-42,500	Closed	-$1.74M	–	223
2020 Q2	$1.74M	Buy	+42,500	New	+$1.43M	0.02%	138

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bellevue Group's VIR Position: Q3 2020 in Review

Bellevue Group sold out of Vir Biotechnology (VIR) in Q3 2020, closing a stake of 42,500 shares — an estimated $1.74M sold.

Bellevue Group first reported a position in VIR in Q2 2020 and held it in 1 quarter. The position peaked at $1.74M in Q2 2020. 119 funds tracked by Wall St. Rank hold VIR as of Q3 2020.

Bellevue Group reported no remaining Vir Biotechnology position as of Q3 2020 after selling out during the quarter.
Bellevue Group sold 42,500 Vir Biotechnology shares in Q3 2020, an estimated $1.74M.
Bellevue Group first reported a position in Vir Biotechnology in Q2 2020 and held it in 1 quarter.
Bellevue Group's Vir Biotechnology position peaked at $1.74M in Q2 2020.
119 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2020.

Based on Bellevue Group's 13F filing for Q3 2020, filed 16 Nov 2020.